Syndax Pharmaceuticals
Price & Volume
Stats
See moreOpen | $15.21 |
Previous Close | $15.03 |
Day Range | $14.87-$15.36 |
52W Range | $8.58-$22.50 |
Market Cap | $1.2B |
Shares Short | 23M |
Financials
See moreRevenue (12 Mos) | $77.9M |
Revenue Growth (YoY) | 984.5% |
Gross Profit (12 Mos) | -$185.4M |
Diluted EPS | -$3.89 |
News
See moreYahoo Finance • 7 days ago
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
Yahoo Finance • 21 days ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Yahoo Finance • last month
Syndax Announces Participation in September Investor Conferences
Yahoo Finance • 2 months ago
Citi ups Syndax target, opens ‘upside catalyst watch’
About
CEO | Mr. Michael A. Metzger M.B.A. |
CFO | Mr. Keith Alan Goldan CPA |
Address | 730 Third Avenue, New York, NY, United States, 10017 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 270 |
